We established the same bilateral tumor model as in Fig. 5c, performed PTT with SGNP@PDA + DOX, and administered isotype control antibody or depleting antibodies targeted against neutrophils (αLy6G), CD4+ T cells (αCD4), CD8+ T cells (αCD8), or NK cells (αAsialo GM1), starting on day 7 to ensure complete depletion of target cells throughout the experimental period (Fig. 7a). The gene discussed is CD8A; the disease is neoplasm.